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Abstract: The vagina is a promising site for both local and systemic drug delivery and represents an
interesting administration route for compounds with poor oral bioavailability. Whereas most of the
currently marketed dosage forms were designed as immediate release formulations, intravaginal
rings (IVRs) offer the possibility of a controlled vaginal drug delivery over several weeks or months.
For a long time, the development of IVRs was limited to steroid-releasing formulations. Recently, IVRs
have witnessed a surge of new interest as promising delivery systems for microbicides. Therefore,
various novel IVR designs have been introduced. To ensure that only safe and effective IVRs will
be administered to patients, it is important to properly distinguish between IVRs with desired and
undesired release performance. In vitro methods for evaluating drug release of IVRs that present
with sufficient predictive capacity for in vivo drug release, and discriminatory power with regard
to IVRs quality, are an essential tool for this purpose. The objective of the present review article is
to present the current status of in vitro drug release testing of IVRs and to critically discuss current
compendial and non-official in vitro drug release methods with regard to their discriminatory power
and in vivo predictivity.
Keywords: intravaginal ring; dissolution method; drug release
1. Introduction
The female vagina is well known as a genital organ with functions related to conception. Whereas
for many years, it was not considered as a site for systemic drug administration and dosage forms
administered to the vagina were intended for local action, more recently, it became obvious that the
vaginal route also offers the potential of delivering drugs for systemic action and uterine targeting.
Thus, nowadays, the vagina is also a promising site of systemic drug delivery and represents an
interesting administration route for compounds with poor oral bioavailability, e.g., proteins [1].
Currently, different types of vaginal dosage forms for both local and systemic action are available
on the market or in clinical development. Commonly used vaginal dosage forms include classical
liquid, semisolid and solid formulations such as solutions, emulsions and suspensions, ointments,
creams and gels, suppositories, pessaries, inserts, tablets and capsules. In the more recent past some
novel types of formulations including foams and films, and more specialized administration devices
such as tampons and vaginal rings were developed. Whereas most of the currently marketed dosage
forms were designed as immediate release (IR) formulations, vaginal rings, also called intravaginal
rings (IVRs) offer the possibility of a controlled vaginal drug delivery over several weeks or months.
The first IVRs were developed as alternatives for long-acting parenterals to provide continuous
medication during a predetermined medication period via the vagina in female mammals. The first
patent application for an IVR was filed in the late 1960s [2], but it took until the early 1990s before
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the first IVRs reached the market. The very first marketed formulation was a contraceptive IVR
containing progesterone (Progering®). Shortly thereafter, IVRs for hormone replacement became
available (Femring®, Estring®). In 2002, the first combined contraceptive IVR, i.e., the NuvaRing®
which releases 120 µg etonogestrel and 15 µg of ethinyl estradiol per day over a 3-week period of
use, was approved by the United States Food and Drug Administration (FDA). Currently, several
long-acting steroid-releasing IVRs that are used in hormone replacement therapy or birth control are
available on the market as seen in Table 1.
Table 1. Currently marketed intravaginal ring formulations (IVRs).
IVR Indication API Status Reference(s)
Estring®
hormone
replacement 17β-Estradiol
marketed
worldwide [3]
Femring®
hormone
replacement 17β-Estradiol-3-acetate
marketed
worldwide [3]
NuvaRing®
& generics
contraception Ethinyl estradiol &etonogestrel
marketed
worldwide [3,4]
Progering®/Fertiring® contraception Progesterone Peru and Chile [3,4]
Annovera® contraception
Ethinyl estradiol &
segesterone acetate FDA-approved [5,6]
Whereas for a long time IVR development was limited to steroid-releasing IVRs, in recent years IVRs
have witnessed a surge of new interest as promising delivery systems for microbicides, which represent
compounds or formulations that can prevent the transmission of the human immunodeficiency virus
(HIV) and other sexually transmitted infections (STIs) [7,8]. Currently, there is also a big interest in the
development of multipurpose prevention devices, i.e., IVRs containing microbicides and contraceptives
to provide protection from both STIs and unintended pregnancy [9–12]. Sub-Saharan Africa remains
the region most affected by HIV and women are at a greater physiological risk of contracting HIV
than men. Overall, HIV/AIDS is the leading cause of death globally in women aged 15–44 [13].
Since every day thousands of women are newly infected with HIV, there is a huge need for novel
treatment and formulation strategies that prevent transmission during sexual intercourse. Vaginal
microbicides promise to address a central gap in current HIV-prevention strategies. Therefore, the
efforts in developing novel microbicide formulations are supported by many non-profit organizations
such as the World Health Organization (WHO), the Population Council or the Bill and Melinda Gates
Foundation. There are no approved microbicides available yet, but currently, it looks like the first
microbicide to be submitted for regulatory approval will be a silicone-based membrane-type IVR
developed by the International Partnership for Microbicides (IPM). This IVR releases dapivirine for
local action in the vagina over the duration of one month [14].
Based on the intended use, the duration of action and the number of drugs to be administered,
various IVR designs are available. An overview of the most frequently used designs is given in
Figure 1. Additional IVR designs can be found in the literature, e.g., in [15]. Figure 1A shows a
schematic view of a reservoir-type IVR, as it is used in the NuvaRing®, the Femring® or the Estring®
device. This IVR type is composed of a drug-loaded core covered by a drug-free membrane [16].
Drug release of reservoir-type IVRs is usually controlled by the nature and thickness of the polymer
membrane. Figure 1B shows a schematic view of a matrix-type IVR, which is the simplest IVR design
and used for the Progering® and the Fertiring®. In the matrix-type IVR, the drug is homogeneously
dispersed/dissolved in the matrix polymer and drug release rates are proportional to both the drug
loading and the surface area of the device [16]. A schematic view of a sandwich-type IVR is depicted
in Figure 1C. A sandwich type IVR consists of a drug-free core surrounded by a drug-loaded polymer
layer, which is covered by a drug-free polymer layer. As in the reservoir-type ring, the outer layer
is intended to control drug release and can either be made of the core polymer or another polymer
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that provides the desired release rate [16]. An innovative ring design, which is called the pod-type
IVR, is shown in Figure 1D. Pod-type IVRs represent a modular design which consists of a drug-free
scaffold with individual polymer-coated drug cores (pellets or tablets), referred to as pods, that are
positioned into premolded, evenly spaced cavities [16,17]. Multiple pods containing different types of
drugs can be placed into a single IVR. Drug release from the IVRs is determined by the individual
coatings of the pods and by the characteristics (e.g., number, geometry, and cross-sectional area) of the
delivery channels in the impermeable IVR structure. Consequently, the pod-type IVR design allows
the simultaneous release of two or more drugs with release rates that can be titrated for each individual
drug or pod [17].
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Since in 1970 the patent “Medicated devices and methods” was granted, the shape of IVRs did not
change [2]. At this time, silicone elastomers were very popular and were used for manufacturing the
first IVRs containing steroids. An advantage of silicone elastomers is their excellent biocompatibility,
but a major disadvantage is the limited availability of medical grade materials. Therefore, within
the following decades other polymers, especially thermoplastic polymers, became more important
in manufacturing IVRs. Frequently used thermoplastic polymers for manufacturing IVRs include
polyethylene vinyl acetate (PEVA) and polyurethane (PU). IVRs made of these polymers are usually
prepared by injection molding or hot-melt extrusion [18–20]. In the recent past, biodegradable polymers,
such as polycaprolactone (PCL) were evaluated as microporous matrices for controlled vaginal delivery
of antiviral microbicides, and are likely to be further investigated in future studies [21–23].
All of the currently marketed IVRs shown in Table 1 rely on a permeation-controlled drug release
mechanism [24], which can be distinguished into three discrete and consecutive steps: (i) drug solvation
in the surrounding polymer, (ii) molecular diffusion of the solvated drug molecules within the polymer,
and (iii) partition of the drug from the ring surface into vaginal fluid [15]. Consequently, the driving
force for drug release from IVRs is passive diffusion down concentration gradients that exist from
within the device to the fluid in the vaginal cavity [15]. However, although diffusion is the driving
force for drug release of all currently marketed IVR formulations, drug release profiles obtained from
membrane-type and matrix-type IVRs are different in nature, and even for the same drug vary with
several formulation parameters like drug load, membrane thickness and polymer type(s). With the
pod-IVRs and some other novel formulation approaches, in the recent past other mechanisms of
drug release beyond permeation control have been investigated, and some of these formulations are
likely to reach the market in the near future [15]. To ensure that only safe and effective IVRs will be
administered to patients, it is important to properly distinguish between IVRs to ensure the desired
in vivo drug release. For IVRs containing multiple drugs, this applies to each individual compound.
In vitro methods for evaluating drug release of IVRs that present with sufficient predictive capacity for
in vivo drug release, and discriminatory power with regard to IVRs with different release rates, are
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thus an essential tool in different stages of formulation development and in quality control (QC) of
finished products.
The objective of the present review article is to present the current status of in vitro drug release
testing of IVRs and to critically discuss current compendial and non-official in vitro drug release
methods with regard to their discriminatory power and in vivo predictivity.
2. Current In Vitro Methods for Evaluating Drug Release of Intravaginal Rings
2.1. Compendial Methods
IVRs are not described in international pharmacopoeia, such as the United States (USP) [25], the
European (Ph.Eur.) [26], the Japanese (JP) [27]. or the International Pharmacopoeia (IP) [28]. According
to the USP, IVRs could be regarded as vaginal systems. According to the USP General Chapter <1151>
systems are preparations of drug substance(s) in carrier devices, which are applied topically or inserted
into body cavities. The drug substances contained in these systems are designed to be released in
a controlled manner over a specified period of time or the drug substance is released based on its
concentration in the formulation. After use, the carrier device is removed [25]. In the scientific literature,
IVRs are described as torus-shaped, flexible, and elastomeric drug delivery devices that can provide
long-term controlled drug release for local or systemic action [3,29–31].
Since in none of the major international pharmacopoeia, a monograph for IVRs is available and
IVRs are also not mentioned in the general pharmacopoeial chapters on dissolution/drug release testing,
it is obvious that compendial dissolution methods do not exist.
2.2. Methods Described in Regulatory Guidances
Neither in the United States, nor in Europe or Japan, is a regulatory guidance on drug release
testing of IVRs available. This is somewhat surprising, since as a result of the NuvaRing® patent
expiry particularly in Europe, in the recent past, numerous generic IVRs have been developed and
were released to the market. Both an increasing number of marketed products, and the numerous IVR
formulations that are currently in development, indicate the need for appropriate in vitro drug release
methods for both in vivo performance prediction and QC.
The Dissolution Methods Database in which the FDA provides information on dissolution
methods, presently recommended by the Division of Biopharmaceutics, Office of Pharmaceutical
Quality to aid industry personnel in developing generic drug products, lists a dissolution method for
an estradiol-containing IVR. Moreover, the need for developing an appropriate in vitro drug release
method for a combined contraceptive ethinyl estradiol/etonogestrel IVR is indicated as shown in
Table 2 [32].
Table 2. Drug release method(s) for IVRs as provided in the FDA Dissolution Methods Database [32].
Drug Apparatus Speed Medium Volume Sampling
Estradiol Incubatorshaker 130 rpm 0.9% saline 250 mL
1, 9, 16, 17, 18,
19, 45 d
Ethinyl
estradiol &
etonogestrel
Develop a method to characterize in vitro release
The method recommended for drug release testing of estradiol IVRs is a quite simple method and
does not even require an official dissolution/drug release apparatus. The dissolution medium to be
applied is isotonic saline solution, which is a medium that does not address fluid properties (pH, buffer
capacity, surface tension etc.) at the administration site. It should be clear that this test method was
mainly designed for QC, i.e., to ensure that the IVR is able to release estradiol with a specific release
pattern and within a certain time frame and to discriminate between good and bad batches rather
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than for simulating in vivo conditions. In some cases, it is possible to correlate in vitro drug release
obtained with such simple in vitro methods with in vivo drug release profiles, but this is then usually
done on a retrospective basis. By contrast, for a proper prediction of the in vivo performance of an IVR,
the physiological conditions that are relevant to in vivo drug release should be properly addressed.
The NuvaRing®, a combined contraceptive ethinyl estradiol/etonogestrel IVR was approved by
FDA in 2002. In the approval documents test of this IVR, conditions for drug release testing were
provided by the manufacturer. Unfortunately, the detailed dissolution method is not accessible by the
public. However, the manufacturer indicates that the test conditions relate to US patent US7357046B2
“Method for dissolution testing of a pharmaceutical delivery device”, which relates to a particular
method for dissolution testing of an annular pharmaceutical delivery device [33]. The approval
documents of NuvaRing® indicate that these test conditions were regarded as appropriate for
obtaining an in vitro-in vivo correlation (IVIVC) for this particular formulation. Even though in the
cited patent there is also no detailed information provided, it is clear that the applied in vitro method
was a quite simple setup with an inert vessel, a device holder that prevents floating of the IVR, a stirrer
to agitate the dissolution medium, and a standard dissolution medium. The NuvaRing® in vitro drug
release method was assessed by FDA quite some time ago and recently several generic formulations of
this IVR have been introduced, however to date, a dissolution method recommendation for formulation
screening of combined contraceptive ethinyl estradiol/etonogestrel IVRs was not published.
2.3. Methods Described in the Relevant Literature
We conducted a detailed literature review of publications about IVRs with a special focus on
research performed in the field of in vitro drug release testing of IVRs. It became obvious, that,
independent of the type of the IVR, in most cases, very simple in vitro setups are applied. Typically,
the IVR is added to a flask/vessel and immersed in dissolution medium. The medium is agitated by
shaking or stirring and the media temperature is controlled throughout the entire experiment. Samples
are removed at predetermined time points and either the sampling volume or the entire media volume
is replaced by fresh medium. Whereas the same general test setup was used in many of the assessed
literature reports, other test conditions, i.e., media composition, volume and temperature, agitation
speed, and sampling frequency were quite different among the different studies. Table 3 gives an
overview of a selection of in vitro test methods with essentially different designs. In the following
sections, the methodological approaches and dissolution media described in the literature will be
discussed in more detail.
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Table 3. Overview of in vitro test methods for release testing of intravaginal rings (IVRs) described in the literature. VFS: vaginal fluid simulant (recipe by Owen and
Katz), AB: sodium acetate buffer pH 4.2 or 4.5, IPA: isopropanol, EtOH: ethanol, PPB: potassium phosphate buffer pH 7.4, E: entire rings were tested, S: segments of
IVRs were tested, R: rods were tested, MSR: macaque-sized ring, SSR: sheep-sized ring, FCP: flux controlled pump, PCL: polycaprolactone, PP: polypropylene, PEVA:
polyethylene vinyl acetate, PLA: polylactide, PDMS: polydimethylsiloxane (silicone), PU: polyurethane, BSA: bovine serum albumin, SDS: sodium dodecylsulfate, and
BAC: benzalkonium chloride.
Author(s) API Ring Material Test Method Formulation Tested Test Medium Agitation andTemperature
Asvadi et al. [21] Acyclovir PCL matrices asinserts for an IVR
Matrices were
immersed in release
medium in PP tubes
S 10 mL of VFS Not specified
Externbrink et al. [34] Ethinyl estradiol andetonogestrel PEVA
Incubator shaker, USP
apparatus 7 (400-DS) E, S
AB and different
hydro-organic media,
100 mL/10 mL
(400-DS)
130 rpm/40 dpm, 37
and 45 ◦C
Wang et al. [35]
Isosorbide
mononitrate,
misoprostol
Silicone elastomer Incubator shaker E 50 mL VFS 60 rpm, 37 ◦C
Mc Conville et al. [36] Tenofovir PLA, PEVA Incubator shaker R 5 mL of VFS 60 rpm, 37 ◦C
Murphy et al. [37] Dapivirine anddarunavir Silicone elastomer Incubator shaker MSR
100 mL of IPA:H2O
(1:1) or VFS 60 rpm, 37
◦C
McConville et al. [38] UC781 Silicone elastomer Incubator shaker R, MSR
100 mL of EtOH:H2O
(1:1) or 1% aqueous
BAC solution;
50 or 100 mL of
IPA:H2O (1:1)
60 rpm, 37 ◦C
Moss et al. [39]
Tenofovir disoproxil
fumarate,
emtricitabine,
maraviroc
PDMS Incubator shaker MSR 100 mL VFS 60 rpm, 25 ◦C
Fetherston et al. [40] MC1220 Silicone elastomer Incubator shaker MSR 50 mL VFS or 200 mLIPA:H2O (1:1)
60 rpm, 37 ◦C
Baum et al. [41] Tenofovir andacyclovir
Silicone elastomer
with PLA pods Incubator shaker E, S 100 mL VFS 60 rpm, 25
◦C
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Table 3. Cont.
Author(s) API Ring Material Test Method Formulation Tested Test Medium Agitation andTemperature
Morrow et al. [42] BSA and monoclonalantibody 2F5 Silicone elastomer Incubator shaker E
30 mL ammonium
acetate buffer 60 rpm, 37
◦C
Loxley et al. [43] UC781 PEVA Incubator shaker E 100 mL IPA:H2O (1:1) 60 rpm, 37 ◦C
Boyd et al. [44] Dapivirine andlevonorgestrel Silicone elastomer Incubator shaker E
50/200 mL IPA:H2O
(1:1) (reservoir vs.
matrix)
60 rpm, 37 ◦C
Srinivasan et al. [45]
Tenofovir disoproxil
fumarate,
emtricitabine and
maraviroc
PDMS Incubator shaker MSR 100 mL VFS 60 rpm, 37 ◦C
Boyd et al. [46] Disulfiram PEVA Incubator shaker E
100 mL 2% SDS
solution or 20 mL
water
60 rpm, 37 ◦C
Boyd et al. [46] Disulfiram PEVA
Dual chambered
release method, in an
incubator shaker
E
Latex balloon with
20 mL of water,
balloons were
submerged in
100 mL of 2% SDS
solution
60 rpm, 37 ◦C
Malcolm et al. [47] TMC120 Silicone elastomer Incubator shaker E 200 mL IPA:H2O (1:1) 60 rpm, 37 ◦C
Malcolm et al. [31]
17β-Estradiol,
17β-Estradiol-3-acetate,
metronidazole,
norethisterone,
norethisterone acetate,
clindamycin,
oxybutynin
Silicone elastomer Incubator shaker E
100 mL 1% aqueous
BAC solution/
phosphate buffer
60 rpm, 37 ◦C
Mc Bride et al. [48] 5P12-RANTES Silicone elastomer Incubator shaker E 15 mL Type 1 water 60 rpm, 37 ◦C
Externbrink et al. [49] Ethinyl estradiol andetonogestrel PEVA
USP apparatus 7
(400-DS) S 10 mL VFS or water
37, 44, 50 and
55 ◦C, 40 dpm
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Table 3. Cont.
Author(s) API Ring Material Test Method Formulation Tested Test Medium Agitation andTemperature
Eder et al. [50] Ethinyl estradiol andetonogestrel PEVA Incubator shaker S 30 mL MilliQ water 130 rpm, 37
◦C
Clark, J. et al. [51] Tenofovir PU Incubator shaker E AB, volume notspecified 80 rpm, 37
◦C
Johnson et al. [52] Tenofovir PU Incubator shaker E 50 mL AB 80 rpm, 37 ◦C
Clark, M. et al. [53] UC781 PU Incubator shaker S
100 mL AB or PPB
containing 2% Solutol
HS-15
80 rpm, 37 ◦C
Mesquita et al. [54]
Nonoxynol-9,
acyclovir, tenofovir
and tenofovir
disoproxil fumarate
PU, PEVA, silicone
elastomer Incubator shaker S
VFS, volume not
specified 80 rpm, 37
◦C
Teller et al. [55]
Dapivirine,
maraviroc, tenofovir
and tenofovir
disoproxil fumarate,
rhodamine B dextrane
PU with flux
controlled pumps Incubator shaker FCPs 20 mL AB 80 rpm, 37
◦C
Traore et al. [56] Hydroxychloroquine PU Incubator shaker MSR S 5 mL AB or 5 mLMRS broth 100 rpm, 37
◦C
Chen et al. [57] Hydroxychloroquine PU Incubator shaker S AB, volume notspecified 100 rpm, 37
◦C
Woolfson et al. [58] Oxybutynin Silicone elastomer Incubator shaker E 100 mL AB 100 rpm, 37 ◦C
Moss et al. [17] Tenofovir andacyclovir Silicone elastomer Incubator shaker SSR and S 100 mL VFS 110 rpm, 25
◦C
Gupta et al. [59] Dapivirine PU ring with rods Water bath shaker S and E 5 mL 25:75 IPA:H2O,50 mL 25:75 IPA:H2O
64 rpm, 37 ◦C
van Laarhoven et al.
[60–62]
Ethinyl estradiol and
etonogestrel PEVA
Automated release
control system E 200 mL water 750 rpm, 37
◦C
Helbling et al. [63–65] Progesterone PEVA USP apparatus 1 E 1000 mL 20: 80EtOH:H2O
25 rpm or
100 rpm, 37 ◦C
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Table 3. Cont.
Author(s) API Ring Material Test Method Formulation Tested Test Medium Agitation andTemperature
Verstraelen et al. [66] Lactic acid PEVA, Eudragit L 100 Incubation S 5 mL demineralizedwater
37 ◦C, agitation not
specified
Xia et al. [67] Anastrozole Silicone elastomer USP apparatus 2 E 250 mL water 50 rpm, 37 ◦C
Pathak et al. [68] Doxycycline PCL matrices asinserts for an IVR Incubation S 10 mL VFS
37 ◦C, agitation not
specified
Ugaonkar et al. [10]
MIV-150,
levonorgestel,
carrageenan, zinc
acetate
PEVA Incubator shaker MSR 10 mL AB 37 ◦C, 100 rpm
Pathak et al. [22] Metronidazole PCL matrices asinserts for an IVR Incubation S 10 mL VFS
37 ◦C, agitation not
specified
Dang et al. [69] Tenofovir PCL matrices asinserts for an IVR Incubation S 10 mL VFS
37 ◦C, agitation not
specified
Moss et al. [70]
Tenofovir disoproxil
fumarate and
maraviroc
PDMS Incubator shaker SSR 100 mL VFS 60 rpm, 25 ◦C
Rotgeri et al. [71] Anastrozole PDMS Incubator shaker MSR
75 mL 1% aqueous
hydroxy-propyl-β-cyclodextrin
solution
100 rpm, 37 ◦C
Reinecke et al. [72] Anastrozole andlevonorgestrel Not specified Incubator shaker Not specified
1% aqueous
hydroxy-propyl-β-cyclodextrin
solution, volume not
specified
37 ◦C, agitation not
specified
Clark, J. et al. [73] Tenofovir andlevonorgestrel PU Incubator shaker E, S
2% Solutol in AB,
volume not specified 80 rpm, 37
◦C
Johnson et al. [74] Pyrimidinedione PU Not specified MSR
2% Solutol in AB or
0.05% Solutol in AB,
volume not specified
Not specified
Murphy et al. [75] Dapivirine andlevonorgestrel Silicone elastomer Incubator shaker E 200 mL IPA:H2O (1:1) 60 rpm, 37
◦C
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Table 3. Cont.
Author(s) API Ring Material Test Method Formulation Tested Test Medium Agitation andTemperature
Johnson et al. [76] Dapivirine andtenofovir PU Water bath shaker S 5 mL 25:75 IPA:AB 64 rpm, 37
◦C
Kaur et al. [77] Dapivirine PU Water bath shaker S 5 mL IPA:AB (25:75) 60 rpm, 37 ◦C
Fetherston et al. [78] Dapivirine andmaraviroc Silicone elastomer Incubator shaker E 200 mL IPA:H2O (1:1) 60 rpm, 37
◦C
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2.4. Methodological Approaches
The so-called shake-flask method is often used to determine drug release from IVRs. A common
setup for a shake-flask experiment is given in Figure 2.
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Figure 2. Schematic view of a shake-flask setup used for determining drug release of IVRs.
Shake-flask experiments are usually performed in an incubator shaker setup. Experiments are
performed with IVRs for human or preclinical use, or ring segments. An individual IVR or a ring
segment is added to a specific volume of a (pre-heated) dissolution medium in a flask (entire ring),
polypropylene tube [21], scintillation vial [34], glass bottle [35], or a sealed flask [36], and placed into
an incubator shaker. The applied media volumes differ between experiments performed with ring
segments, rings for preclinical use, and human IVRs. When testing ring segments, media volumes are
usually small (5–20 mL per segment). The highest media volume reported for testing entire IVRs is as
high as 1000 mL [63–65]. Preclinical in vivo drug release studies are often performed in macaques.
Since IVRs for human use do not fit into the vaginal cavity of female macaques, IVRs with a smaller
diameter are used for these experiments. Consequently, the volumes of test media used for in vitro
drug release experiments with macaque-sized IVRs are often significantly smaller than those used in
human IVR experiments [24,37–40]. The reported agitation speeds in shake-flask experiments range
from 60 rpm [31,35–48,70,75,78–80] through 80 rpm [51–54,73], 100 rpm [10,56–58,71] and 110 rpm [17]
to 130 rpm [34,49,50,81,82].
Besides the incubator shake-flask method, several other in vitro setups have been described.
Gupta et al. used a water bath shaker agitated at 64 ± 2 rpm for determining dapavirine release
from a polyurethane IVR [59]. Van Laarhoven et al. used an “Automated release control system” in
which the medium was stirred with an agitation rate of 750 rpm for studying etonogestrel and ethinyl
estradiol release from combined contraceptive IVR formulations [60–62]. Some research groups also
used compendial apparatuses. Helbling et al. used the USP apparatus 1 (basket) with the aim of
determining progesterone release from the commercial Progering® and an EVA-based IVR containing
progesterone, and to further identify the main factors that influence the drug release rate of EVA-made
IVRs [63–65]. In their experiments, the rings were placed in stainless steel baskets agitated at 25 rpm
or 100 rpm [63]. 1000 mL of an ethanol:water mixture (20% ethanol v/v) was used as the dissolution
medium. At pre-determined time points, samples of 5 mL were taken and the sampling volume was
replaced by fresh medium [64]. In a subsequent study, Helbling et al. used the same experimental
setup to evaluate different cellulose membranes for their potential to eliminate the extensive burst
release of progesterone (20–40% progesterone release within a short initial burst phase) that had been
observed in the previous studies with EVA-based rings [65].
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Externbrink et al. used a small volume USP apparatus 7 (400-DS, Agilent Technologies) to study
drug release of the NuvaRing® with the aim of establishing accelerated test conditions that can provide
real-time release profiles within a very short test duration [49]. Experiments were performed with
NuvaRing® segments that, prior to the experiments at both ends, had been sealed with Loctite®
acrylate glue to ensure that drug release was solely controlled by the ring membrane. Release
experiments were performed at different temperatures, i.e., 37, 45, 50 and 55 ◦C. 10 mL of Vaginal
Fluid Simulant (VFS) with 0.1% sodium azide was used as release medium. Sampling was performed
automatically and sampling intervals were adjusted at elevated temperatures. By weighing entire rings
and all corresponding ring segments, drug release profiles obtained for the individual segments were
standardized to that of the entire ring via the mass ratio (segment/entire ring). Using the instrumental
setup, but acetate buffer pH 4.50 as release medium, Externbrink et al. also evaluated etonogestrel and
ethinyl estradiol release of a matrix-type IVR in real-time and accelerated test conditions [34]. In both
studies the shake-flask method was used as reference method. Eder et al. studied etonogestrel and
ethinyl estradiol release from cylindrical reservoir co-extrudates made of different types of PEVA [50].
They placed the individual co-extrudate prototypes in an USP I basket to avoid floating during drug
release studies. The baskets were then transferred into flasks filled with 30 mL of pre-heated MilliQ
water, which were placed in an incubator shaker at 37.0 ◦C and agitated at 130 rpm. Samples were
collected in 24 h intervals and a full media change was performed after each sampling.
Recently, McBride et al. presented a novel ring design, the so called exposed-core IVR comprising
one or more drug-loaded hydroxypropyl methylcellulose (HPMC) cores exposed to the external
environment via orifices or windows in an overmolded silicone sheath [48]. Drug release of these
novel IVR types was studied in a very simple setup, i.e., poylpropylene tubes containing 15 mL of
MilliQ water of 37 ◦C. The tubes were placed in an incubator shaker and agitated at 60 rpm throughout
the experiment. Samples were taken periodically with complete media replacement.
In the course of developing PEVA-based disulfiram-loaded vaginal rings for the localized treatment
of cervical cancer, Boyd et al. evaluated a novel method that had been designed to better mimic
conditions in the vagina, i.e., the aqueous environment in the vaginal vault which is surrounded by
hydrophobic tissue [46]. A sealed latex balloon simulated the vaginal wall and was filled with 20 mL
water to mimic vaginal fluid. First, the IVR was immersed in the aqueous phase inside the balloon
(inner compartment). Then, then the balloon was sealed and placed into a flask containing 100 mL of
2% sodium dodecyl sulfate (SDS) solution (outer compartment). Subsequently, the flask was placed
into an orbital shaking incubator and agitated at 37 ◦C and 60 rpm. The experiment was run for 14
days and samples were taken daily from both the inner and outer compartment. At each sampling
point, a full media change was performed for both compartments.
2.5. Release Media
In vitro drug release of IVRs is either performed for QC or for predicting in vivo drug release.
Dissolution methods to be applied in QC should be discriminating and robust and need to ensure
that drug release is controlled by the dosage form rather than the test conditions. A biopredictivity
is not required. Therefore, QC methods are usually of simple design comprising a standard test
apparatus and simple aqueous dissolution media. As stated before, only one “official” QC method for
an IVR, describing the use of 0.9% saline solution as a dissolution medium for an estradiol IVR, can be
found in the FDA dissolution methods database. For all other marketed IVRs, there is no information
on officially accepted dissolution media available. However, other media used for evaluating drug
release of IVRs can be found in the scientific literature. The least complex medium used for QC
purposes is water. Due to its lacking buffer capacity in pharmaceutical dissolution, testing water is
also one of the least reliable media for dissolution testing, and its use in in vitro drug release testing
of IVRs is not very common [46,48,50,61,66,67]. Sink conditions are an essential prerequisite for
in vitro dissolution test methods used in QC. As the fluid volume applied in in vitro drug release
testing of IVRs is usually small, but many of the relevant APIs are poorly soluble, selection of an
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appropriate dissolution medium is essential for ensuring sink conditions throughout the experiment.
The addition of surfactants to aqueous dissolution media can be an appropriate means for this purpose.
Boyd et al. acquired in vitro drug release data of their disulfiram-loaded PEVA vaginal rings in a
2% SDS solution [46]. Externbrink et al. added 0.3% SDS to their release medium to increase the
solubility of etonogestrel and ethinyl estradiol [34]. A rarely used surfactant in dissolution testing is
benzalkonium chloride (BAC). Malcolm et al. studied in vitro drug release from steroid-containing
rings in an aqueous solution containing 1% (w/w) BAC [31], and McConville et al. used an aqueous
1% (w/v) BAC solution for determining in vitro release of UC781, a topical microbicide from human
and macaque-sized IVRs [38]. Besides applying artificial surfactants to increase API solubility in an
aqueous dissolution medium, there are several other options for obtaining sink conditions. Various
groups reported the addition of cyclodextrins for this purpose, and used a nonbuffered aqueous 1%
2-hydroxyl-propyl-β-cyclodextrin solution for drug release testing of IVRs containing anastrozole [71],
levonorgestrel [83], and fixed-dose combinations of anastrozole and levonorgestrel [72]. The use of
hydroalcoholic media is another means of increasing API solubility in the dissolution medium. Several
research groups reported the use of hydroalcoholic/hydro-organic media for determining drug release
from IVRs [34,37,38,40,43,44,47,59,63–65,75–80]. However, even though they might be the perfect
choice for providing sink conditions for some IVRs that contain poorly soluble drugs, they also can
cause significant problems and therefore their use should be well understood.
Some hydro-organic media are able to penetrate into polymers and cause polymer swelling. By
doing so, they can alter the API diffusion characteristics in the polymer and thus impact overall drug
release kinetics. In that case, they are unlikely to be applicable in QC, since drug release is no longer
determined by the quality of the IVR, but dependent on the composition of the dissolution medium
applied in the in vitro experiments. Therefore, when using hydro-organic release media, the degree of
swelling should be determined and compared with that in pure aqueous media [34]. If the medium does
not affect the release mechanism of the IVR, it can be applied for dissolution method design. Different
organic solvents have been applied in hydro-organic release media. Helbling et al. used a water:ethanol
mixture with an ethanol content of 20% (v/v) to determine progesterone release from EVA-IVRs [63–65].
McConville et al. determined drug release from UC781-loaded human-sized IVRs in a mixture of
ethanol:water (1:1 v/v) [38]. For macaque-sized IVRs of the same type they used an isopropanol
(IPA):water (1:1 v/v) mixture [38]. A particular reason for using two different types of solvents was not
indicated by the authors, however due to the poor aqueous solubility of UC781, the use of IPA might
have provided more reliable sink conditions. Overall, the use of IPA:water mixtures for screening drug
release from IVRs was reported by many research groups [34,37,38,40,43,44,47,59,75–80]. Provided
that the use of an organic solvent does not affect the general release mechanism of a drug-loaded IVR
and the release rates obtained in water are proportional to those obtained in organic solvent:water
mixtures, hydro-organic media also represents an appropriate means to accelerate drug release from
polymer matrices. Externbrink et al. used mixtures of ethanol:water, IPA:water and acetonitrile:water
with 25%, 50% or 75% organic solvent to accelerate drug release from a matrix-type IVR containing
etonogestrel and ethinyl estradiol [34]. The release rate of both drugs increased with increasing solvent
concentration, whereas with acetonitrile:water mixtures the strongest degree of acceleration was
achieved. The same researchers also studied the impact of hydro-organic mixtures and temperature,
and found out that combining a high organic solvent content and an increased media temperature
resulted in the highest release rates for the formulations studied, without affecting the general release
mechanism of the respective IVR [34].
As can be seen in the methods listed above, in many of the published in vitro QC test designs, no
attention was given to properly address the composition and properties of vaginal fluid. However,
some researchers tried, at least, to properly simulate vaginal pH-conditions. Woolfson et al. studied
oxybutynin release from a silicone-based vaginal ring in a pH 4.0 (10 mM) acetate buffer [58]. Other
research groups report the use of acetate buffers in a pH range of 4.0–4.5 [10,34,51–53,55,56,58].
A commonly used medium that well addresses average human vaginal fluid pH is 25 mM acetate
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buffer pH 4.2 [51–53,55]. Similarly, when the aim is to get an idea of vaginal drug release in rabbits, a
species which is often used in the preclinical evaluation of vaginal ring segments, phosphate buffered
saline (PBS, pH 7.40) represents a simple, but with regard to vaginal pH relevant medium, since rabbits
typically have a neutral vaginal pH [73]. When addressing human vaginal pH conditions, acetate
buffer is used as such or with some surfactant added when sink conditions cannot be obtained with the
pure aqueous buffer medium. Surfactant concentrations vary between studies. Johnson et al. screened
pyrimidinedione-loaded PU rings in 25 mM sodium acetate buffer pH 4.2, containing 0.05% or 2%
Solutol® HS 15 (poly-oxyethylene esters of 12-hydroxystearic acid, nowadays also known as Kolliphor®
HS 15) [74]. The buffer containing 0.05% Solutol® HS 15 had been selected as the non-sink release
medium in which the surfactant concentration was above the critical micelle concentration and therefore
resulted in pyrimidinedione solubilization, i.e., a higher amount of pyrimidinedione dissolved than in
the same volume of surfactant-free buffer. However, the effective surfactant concentration was too low
to overcome pyrimidinedione saturation in the course of the experiments. By contrast, a concentration
of 2% Solutol® HS 15 resulted in sink conditions for the pyrimidinedione dose tested. The cumulative
release profiles obtained in these two media were quite different. Under sink conditions, the IVR
showed matrix-controlled release kinetics, whereas under non-sink conditions partition-controlled
kinetics could be observed [74]. From these experiments, it could be clearly seen how the surfactant
concentration can affect in vitro results obtained from IVRs containing poorly soluble compounds.
The use of 2% Solutol® HS 15 to provide sink conditions in experiments targeted on determining
drug release of poorly soluble drugs from different types of IVRs was also reported by several other
authors [53,73].
Using media with physiological vaginal pH represents a first setup towards physiologically
relevant dissolution media for IVRs. Based on an intensive literature review in 1999, Owen and Katz
introduced a “Vaginal Fluid Simulant” (VFS) that was developed to mimic properties and composition
of human vaginal fluid [84]. VFS has a pH of 4.20 and is composed of: 3.51 g NaCl, 1.40 g KOH, 0.222 g
Ca(OH)2, 0.018 g bovine serum albumin, 2.00 g lactic acid, 1.00 g acetic acid, 0.16 g glycerol, 0.4 g urea,
and 5.0 g glucose. Although it is clear that this medium does not contain all ingredients of human
vaginal fluid and also does not address the huge intra- and interindividual variability in vaginal fluid
composition and properties, it represents the first step towards a more biorelevant test medium that
can be applied in QC, and to some extent might be predictive for in vivo conditions. Therefore, it is
currently widely used in IVR drug release testing. For this purpose, the medium is either used as
such [21,22,35,40,68,69], or with slight modifications in osmolality [17,24,39,41,45,70]. Moreover, some
authors added a preservative, such as sodium azide (0.1%) to VFS to prevent the growth of undesired
bacteria and molds [49].
2.6. Entire Rings vs. Segments and Their Materials
During the early stage in development of an IVR, particularly for simply membrane- or
matrix-based IVR types, it may be useful to screen a drug loaded polymer strand or just a part
of an IVR. Determining drug release from IVR segments can minimize the amount of materials needed
for fabrication (i.e., ring polymer, drugs and others), and reduces the amount of solvents/medium
required for a drug release experiment. It is, thus, a valuable analytical approach to be applied in
formulation development and screening, and is particularly attractive, when the final ring has not
been manufactured yet.
When testing ring segments of reservoir, matrix or sandwich type IVRs, it is crucial to seal the ends
of the segments to prevent drug release from the cut surface. Various techniques for sealing the segment
ends have been described. These range from using the ring polymer [22,68,69] or a similar polymer [73]
through dip coating of the cut surfaces in PVP or PVA solutions [57], to the use of an impermeable
glue. To determine drug release from steroid containing IVR segments, a sealing made of Loctite® and
1/16-inch thick polyethylene sheets proved to be impermeable for steroids [34,49,53,59,61,77]. In any
case, sealing the ends of the segments must provide a release geometry equivalent to that of an entire
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ring. Thus, when testing drug release from ring segments, it is crucial to measure the exact length and
diameter, as well as the mass of the segment, before starting the experiment. Clark et al. scaled their
release rate values obtained from segments by extrapolating the surface area to that of a full-sized
ring [53]. An alternative approach was used by Externbrink et al. who normalized release profiles
obtained from segments to release of an entire IVR, based on the mass ratio (segment/ring) [34].
2.7. Temperature
With regard to the physiological conditions in the vaginal cavity, drug release tests should
be performed at 37 ◦C. Whereas 37 ◦C is the “standard” test temperature applied in many
dissolution test methods, for IVRs, various test methods applying a temperature of 25 ◦C have
been described [17,24,39,41,70].
Externbrink et al. studied ENG release from the NuvaRing® at different temperatures ranging
from 37 ◦C to 55 ◦C [49]. The aim of their study was to investigate if temperature can be applied to
accelerate drug release from membrane-type IVRs. For this purpose, a small volume USP apparatus
7 was used and IVR segments of ~1–1.5 cm length were tested. Length and mass of the entire IVR
and each individual segment was measured, and drug release was normalized to the IVR mass.
Real-time drug release was determined at 37 ◦C in 10 mL of VFS or water. Additional experiments were
performed at 44, 50 and 55 ◦C to accelerate drug release [49]. The release profiles obtained at different
temperatures were then examined for an Arrhenius relationship. Drug release rate increased with
increasing temperature, but still followed zero-order kinetics. An Arrhenius relationship was achieved
for rate constants calculated from real-time release and temperature-accelerated release profiles with
adjusted sampling time points.
In another study, Externbrink et al. used the same test setup for assessing drug release from
matrix-type IVRs at 37 ◦C and 45 ◦C [34]. Additionally, for this IVR type, higher drug release rates
could be observed at elevated temperature.
Clark et al. investigated levonorgestrel diffusivity in different polyether urethane polymers (PEUs)
at different temperatures, i.e., 23, 37 and 50 ◦C [73]. For this purpose, segments of 15 mm length
were end-capped and the exact length, diameter and mass were determined. LNG diffusivity was
calculated for each individual segment and increased with increasing temperature. Moreover, the
extent of acceleration of drug release differed between the different PEUs.
In all of the cited experiments, it was shown that temperature is a critical parameter in dissolution
method design, but also an appropriate means to accelerate drug release. Provided that a linear
relationship can be established between real-time and accelerated drug release at increased temperatures,
experiments performed at elevated temperatures can be an important tool for QC, since properly
validated accelerated drug release experiments can be performed within a much shorter time than real
time experiments.
2.8. Presentation of Data
In most of the publications cited in this review, results of drug release experiments are either
presented as cumulative release, as daily release rate of the respective API, or both. To gain an idea, if
the drug(s) is/are released from an IVR in a constant manner, presentation of the results as daily drug
release can be of great advantage. By contrast, presentation of an average daily rate may underestimate
essential details, for instance, a burst release immediately after application of the IVR or overestimate
drug release in the phase of constant release. Sampling intervals can influence the proper detection of
a burst release during the first hours or day(s) of drug release. Burst release phenomena have been
observed for IVRs made of condensation-cure silicone and for reservoir-type IVRs during storage [58].
A burst release is characterized by an initial higher drug release rate compared to the claimed daily
release rate.
As during an initial burst release, plasma concentrations can be much higher than the desired
plasma concentration, and for certain drugs this can present with serious side effects or even toxic
Pharmaceutics 2019, 11, 538 16 of 23
effects. Therefore, the burst release of an IVR should be well characterized. Thus, during the first
24–72 h of the experiment, an increased sampling frequency should be considered. After the initial
phase of drug release, the sampling frequency can be reduced. However, as possible, daily release
should be determined over the entire release period, since information on the release rates during
different time periods (for example, day 1, 2–7 days, 8–14 days, 15–21 days, etc.) can be helpful for
both developing discriminative QC methods or estimating in vivo drug release [44,57,67,71,83].
3. Discussion
By reviewing the official drug release methods available in international pharmacopoeias and
guidelines, and the in vitro methods for assessing drug release of IVRs described in the literature,
it became obvious that, to date, neither a standardized in vitro drug release method for QC, nor a
biopredictive in vitro method for IVRs had been described. Various parameters that can affect drug
release from an IVR are discussed in this review article. In vitro parameters include the apparatus
design and the agitation rate, the volume, the composition and the temperature of the dissolution
medium. Essential formulation parameters include the API solubility in the proposed test media as
well as the IVR design. Finally, the analyst should be aware that the sampling schedule can have a
significant impact on the obtained drug release profile.
Since the number of IVRs is likely to significantly increase within the near future, these systems
should be monographed in international pharmacopoeias. Future research activities in assessing drug
release of IVRs should focus on designing both biopredictive in vitro dissolution methods, as well as
robust and discriminative QC methods that can be implemented in international pharmacopoeias
and guidances.
Biorelevant test conditions should properly address the in vivo situation, i.e., the volume and
composition of vaginal fluid [85] and the temperature in the vaginal vault. Attention should also be
paid to the need of simulating changes in the vaginal microenvironment during the menstrual cycle,
ageing or due to sexual intercourse. During sexual intercourse, human vaginal fluid mixes with human
seminal fluid. This results in a temporary increase of vaginal pH due to the alkaline pH of human
semen [86]. The pH increase will particularly affect drug release and dissolution of pH-sensitive
drugs and a test setup simulating sexual intercourse should thus be considered when designing
in vitro methods for IVRs that contain ionizable compounds. Human vaginal fluid contains various
proteins [87]. Since biorelevant dissolution media are typically designed to reflect essential properties
of the physiological fluids available at the site of drug administration/release, various simulated vaginal
fluids contain proteins, for instance, albumin [7,84,88,89]. In drug release experiments with media
containing proteins, drug-protein binding, which is, e.g., well known for steroids [30,90–93], should
be properly addressed to capture the entire amount of drug released from the IVR. In such cases,
the extent of protein binding should be evaluated in preliminary experiments by determining the
recovery of different concentrations of an API dissolved in the simulated vaginal medium of interest.
The use of biorelevant media can also present with challenges regarding microbial stability, since some
biorelevant media provide excellent conditions for bacterial growth. Consequently, the addition of a
preservative can be necessary to prevent biorelevant media from growth of undesired bacteria and
molds. The selected preservative should be compatible with the other components of the medium
and with the respective API. Overall, if biorelevant media are intended to be applied in in vitro drug
release experiments of an IVR, the solubility and stability of the respective API should be investigated
prior to the release experiments.
Currently, an increasing interest in developing IVRs can be observed. Formulation development
of both generic IVRs and the design of novel IVR types would highly benefit from biopredictive
in vitro dissolution methods. Since primary in vivo studies are often performed in animals such as
rabbits [53,73,94], sheep [17,52,70], and macaques [10,17,24,37–40,45,71,74,79], appropriate in vitro
models simulating the physiological environment in these animal species might also be required.
McConville et al. tried to establish an IVIVC between in vivo data obtained in macaques and in vitro
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drug release data obtained with the macaque-sized IVR, but failed due to the lack of a predictive
in vitro drug release method [38]. This is a clear indicator for the need of developing physiological
relevant in vitro dissolution methods for these dosage forms. Recently, Boyd et al. presented an
approach to better address intravaginal conditions in an in vitro dissolution experiment by applying a
small volume of dissolution medium and mimicking vaginal tissue with a latex balloon [46]. This was
another step forward in terms of a biorelevant test design, however, the proposed model is still far
from a biopredictive in vitro model for IVRs.
Whereas most of the in vitro methods discussed in the present manuscript addressed a proper
use of an IVR, human factors might be another fact to consider in future method designs. Independent
of the IVR design and the drug(s) to be delivered, IVRs are designed to provide controlled drug release
over extended periods of time and should ensure a safe and effective drug therapy and a good patient
adherence. However, women’s use of a ring may deviate from perfect use [95]. The IVR might, for
instance, be intentionally removed or be expelled periodically. Recently, Murphy et al. presented
results of an in vitro study targeted on simulating the imperfect use of a dapavirine-releasing IVR [95].
They addressed the impact of systematic deviations (removal and storage of the IVR for different
time periods) from a 28-day continuous-use protocol upon release performance. Furthermore, they
assessed the effect of ring exposure to a range of common household chemicals and cosmetics, that in
real-life conditions might be used for IVR cleansing or vaginal hygiene, on drug load and stability [95].
Even though the in vitro release experiments performed in the cited study were performed in a typical
shake-flask setup and thus, cannot necessarily be regarded as biorelevant, the human factors addressed
in this study might also be a facet to be considered in biorelevant test designs.
Particularly for drugs with limited solubility, the application of a biorelevant fluid volumes and
composition in an in vitro experiment might not necessarily be the key for a successful prediction of
the drug´s plasma level over the recommended time of use of the respective IVR. If typical vaginal fluid
volumes will be used in a closed dissolution setup, such as e.g., the shake-flask setup, many drugs are
likely to reach their saturation concentration within the first hours or days of the experiment. This will
either stop further release or result in drug precipitation. Since in vivo drugs that had dissolved in
vaginal fluid can be absorbed via the vaginal mucosa, drug concentration in the vaginal fluid will
typically be much lower than in the in vitro setup, and the total amount of drug absorbed over the
recommended time of IVR use is likely to be much higher than could be predicted from dissolution
experiments run in such a closed dissolution system. Consequently, besides properly addressing
vaginal fluid volume and composition, drug transport across the vaginal mucosa should also be
considered in a biorelevant test design. Consequently, it might be worthwhile to evaluate dynamic or
compartment models for this purpose. Based on these considerations, it will hopefully be possible to
establish more biorelevant in vitro models in the near future.
In vitro dissolution methods applied in QC of IVRs should enable to distinguish between
products/batches with the intended or undesired drug release. The use of a biorelevant test setup is,
thus, not an essential requirement for method design. By contrast, QC methods are often characterized
by a simple and robust test design with sufficient discriminatory power. Since IVRs represent dosage
forms that release the API over a time range of weeks or even months, accelerated test methods
can prove as a helpful tool in determining drug release and batch conformity of these systems.
For developing accelerated in vitro drug release methods media, temperature or composition can be
altered and elevated temperatures, the use of hydroalcoholic/hydro-organic solvents, or combinations
thereof, have already been successfully applied to accelerate drug release from IVRs. A general
prerequisite for applying such conditions is that they accelerate drug release, but do not alter the release
(diffusion) mechanism [34]. To assess the impact of media composition on in vitro performance of the
IVR, the swelling of an IVR should be recorded during the course of an in vitro release experiment to
check whether the diffusion mechanism is affected by media composition or not. Moreover, for IVRs
made of thermoplastic materials the temperature during in vitro release experiments should be strictly
controlled [49], since even a small increase in temperature can increase the drug release rate. In QC,
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maintaining sink conditions is also of great importance to ensure that drug release is determined
by the dosage form rather than by the in vitro test conditions. Sink conditions are a particular issue
when assessing drug release from IVRs containing poorly soluble drugs, and can be achieved by either
applying large volumes of dissolution media, or by adding surfactants to the dissolution media.
Unexpectedly, some experiments performed in the recent past have shown that the media volume
can influence the drug release even when sink conditions are maintained [34]. Therefore, when
dissolution experiments are performed in a closed system, such as the shake-flask setup, drug release
should be determined in different media volumes to ensure the robustness and reliability of the test
method. In experiments run with fixed media volumes, the renewal rate (sampling time points,
sampling volumes) of the release medium can also have an impact on the drug release rate [46].
This impact should also be addressed in method design. A higher sampling frequency during the
first day of the release experiment should be considered, when a burst release is expected to properly
capture the burst release in the in vitro drug release profile.
Drug release testing of IVR segments can be helpful in formulation development or batch
conformity testing when drug release of IVR segments is predictive for drug release of an entire ring.
However, for method validation, studies with entire rings and ring segments should be performed to
ensure the predictivity of release rates estimated from drug release experiments with ring segments,
with regard to drug release of an entire IVR [34,49,53,73].
Due to expiring patent protections of existing IVRs, and the need for novel IVR formulations for
HIV prevention and long-acting IVRs for contraception, hormone replacement therapy or treatment
of endometriosis, regulatory agencies will be confronted with a variety of new drug applications.
Currently, it does not seem to be clear what kind of in vitro data would be required for a successful
application for an IVR, i.e., if cumulative or daily release should be plotted, if it is legal to calculate
average daily release rates rather than providing detailed information on the variations in daily release
over time, or if the chance for a burst release should be screened in more detail.
The information provided in the present review will, hopefully, be a platform for a more detailed
discussion between academia, industry, and regulatory authorities on how robust and predictive
in vitro drug release methods for IVRs should be designed to ensure safety and efficacy of these
dosage forms.
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